Regeneron (REGN) Tops Q2 EPS by 104c, Sales Beat

Regeneron (NASDAQ: REGN) reported Q2 EPS of $4.17, $1.04 better than the analyst estimate of $3.13. Revenue for the quarter came in at $1.47 billion versus the consensus estimate of $1.35 billion.

Raised estimated full year 2017 EYLEA U.S. net sales growth guidance to approximately 10% over 2016.

"In the first half of 2017, we continued to bring our market-leading therapy EYLEA to more patients with retinal diseases, resulting in strong global sales. We also markedly expanded our positive impact on patient lives with two important new product launches for serious diseases, Dupixent for moderate-to-severe atopic dermatitis and Kevzara for moderately to severely active rheumatoid arthritis," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. "The Dupixent U.S. launch in moderate-to-severe atopic dermatitis is proceeding well, with a very positive reception in the physician and patient community and strong commercial execution. In the second half of the year, we anticipate EU approval for Dupixent in atopic dermatitis, as well as Phase 3 study results and a potential U.S. regulatory submission for Dupixent in uncontrolled asthma."

For earnings history and earnings-related data on Regeneron (REGN) click here.

You May Also Be Interested In

• Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
• Regeneron Pharma (REGN) PT Lowered to $854 at Piper Sandler
• Goldman says rotation driven by positioning, not fundamentals